
Axsome Therapeutics gets 'Outperform' rating on strong drug pipeline and FDA NDA acceptance for narcolepsy drug.
Axsome Therapeutics received an "Outperform" rating from BMO Capital due to significant progress in its drug pipeline, including FDA acceptance of its NDA for AXS-12, a narcolepsy treatment with a PDUFA date set for May 1, 2027. The company is also a...


